🔗 Share this article

As the United States proceeds with unprecedented adjustments to its immunization recommendations, a particular individual has surfaced somewhat surprisingly: Tracy Beth Høeg, a Danish American sports physician and public health researcher who first made her name by questioning Covid vaccinations throughout the pandemic and has concentrated on alleged fatalities after Covid vaccination in her short tenure at the Food and Drug Administration.

Proposed Changes to Pediatric Immunization Schedule

Health officials had intended to unveil radical revisions to the childhood vaccine schedule recently, synchronizing the US with the Danish immunization schedule, sources say – a significant shift that would put the US out of step with much of the world with little proof for public health gain. This reveal has been postponed until the next year.

Instead of Vinay Prasad, Høeg is set to present at the gathering. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth individual to head the division this year.

Consolidating Power at the Regulatory Body

This interim role may indicate a tighter collaboration between the drug and biologics divisions as Høeg and Prasad strengthen their influence at the FDA – and it points to a increased emphasis upon rolling back previously authorized vaccines at the FDA.

Høeg has often pushed for discontinuing certain pediatric immunization guidelines in the US in order to be more similar to the Danish model, a nation with comprehensive healthcare and a citizenry about the population of Wisconsin’s.

In her initial public appearances, she has continued to focus on vaccination policy – traditionally the domain of Dr. Prasad, chief of the FDA’s CBER – as opposed to medication approval.

Concerns Over Qualifications

Høeg has little discernible track record in medication creation, oversight or administrative roles, which has been standard for past heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the FDA chief and CBER since March.

“She appears not to have any of the qualifications” for overseeing the pharmaceutical oversight division, stated Jonathan Howard. “She’s never run a randomized controlled trial. She lacks experience in leading a large organization. She is not an expert in industry regulation.”

Previous heads of CBER would “grasp laws and regulations and the underlying principles of drug development”, said a former acting FDA commissioner. “Clearly, she lacks the sort of resume that former directors who ran the center have had.”

CDER has an vast range of responsibilities at the FDA, the former commissioner emphasized.

“The public just focuses on the new drug program, but the off-patent medication office authorizes thousands of generic medications. There is also a biologic copycat branch, OTC medication office and more, and all of those must be looked after,” Dr. Woodcock explained. “The area you neglect, that is the part that I always told people is going to bite you.”

Furthermore, a substantial administrative aspect to the role, which supervises over 5,000 staff members. “It’s a massive management job, if you do it right,” Woodcock concluded.

Response and Contentious Policies

When asked about concerns about Høeg’s credentials and whether this assignment indicates increased cooperation among agency officials on immunizations, a spokesperson stated that the “questions stem from flawed premises”.

“This background aligns with the responsibilities of her role,” the spokesperson explained, citing the period Høeg spent counseling the FDA commissioner on “medication safety and approval science, including computational safety modeling and vaccine surveillance”.

As the temporary head, Høeg inherits the commissioner’s recently launched priority voucher program, a contentious rapid therapy clearance system that allegedly concerned her predecessors. “By what process are these medications being picked for this expedited pathway? Who makes the choices?” Howard asked. “There’s a lot of secrecy occurring at the regulatory body right now.”

In general, he stated, “the FDA seems to be moving towards laxer oversight of all drugs, aside from immunizations.”

Public Track Record on Vaccines

Regarding immunizations, Dr. Høeg has a more documented, if problematic, track record, critics observe. She published a analysis using unconfirmed volunteer-provided data to determine the incidence of heart inflammation after Covid vaccination. She consulted for the Florida surgeon general Joseph Ladapo, who was said to have altered data to indicate COVID-19 vaccines are riskier than they are.

Part of her “wish list” for the current administration included changing guidelines for novel immunizations and ending “optional” immunizations, she remarked following the vote on a podcast. At the agency, Høeg has reportedly proposed preventing young men from obtaining Covid vaccinations.

“She is an complete dogmatist who commences with her preconceived notions and tailors the evidence to retrofit the data in a very deceptive, fraudulent fashion,” Howard argued.

Consolidating Power and a “Push for Payback”

Høeg became part of fellow dissenters, {like|